[EN] INHIBITORS OF 11ß -HYDROXYSTEROID DEHYDROGENASE TYPE 1<br/>[FR] INHIBITEURS DE LA 11?-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE DE TYPE 1
申请人:VITAE PHARMACEUTICALS INC
公开号:WO2009108332A1
公开(公告)日:2009-09-03
This invention relates to novel compounds of the Formulae I or II and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD l in mammals.Formula (I).
INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1
申请人:Claremon David A.
公开号:US20110034455A1
公开(公告)日:2011-02-10
This invention relates to novel compounds of the Formula (I*), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of Cortisol in a cell or the inhibition of the conversion of cortisone to Cortisol in a cell.
The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.
SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS
申请人:Eidam Hilary Schenck
公开号:US20080318990A1
公开(公告)日:2008-12-25
The present invention relates to a compound of the following formula:
where R
1
-R
6
, R
10
, Y, n, m, p, and q are as defined herein. Compounds and compositions of the present invention are useful for the treatment of diseases associated with the overexpression of CCR2.